SCHEMBL8718453

SCHEMBL8718453

C[C@H]1CCC[C@H](O)O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13451839 1.00
SCHEMBL13018033 1.00
SCHEMBL14450741 1.00
SCHEMBL8720661 1.00
SCHEMBL6693398 1.00
SCHEMBL8720729 1.00
SCHEMBL2302484 1.00
SCHEMBL13017712 1.00
SCHEMBL17850799 0.94
SCHEMBL12473315 0.92 CA1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3760233-B1 ONE-POT PREPARATION PROCESS FOR ANTIBODY DRUG CONJUGATE INTERMEDIATE MABPLEX INT CO LTD (CN) 2023-07-12 EP disclosed
WO-2023083716-A1 ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-05-19 WO disclosed
EP-3760233-A1 ONE-POT PREPARATION PROCESS FOR ANTIBODY DRUG CONJUGATE INTERMEDIATE Mabplex International, Ltd. (CN) 2021-01-06 EP disclosed
EP-3461845-B1 ANTI-CD33 ANTIBODIES AND IMMUNOCONJUGATES GENENTECH INC (US) 2020-09-16 EP disclosed
EP-3191135-B1 ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES GENENTECH INC (US) 2020-08-19 EP disclosed
EP-3191134-B1 ANTHRACYCLINE DISULFIDE INTERMEDIATES, ANTIBODY-DRUG CONJUGATES AND METHODS GENENTECH INC (US) 2019-11-20 EP disclosed
EP-3046940-B1 METHODS OF USING ANTI-LGR5 ANTIBODIES HOFFMANN LA ROCHE (CH) 2019-07-03 EP disclosed
EP-3461845-A1 ANTI-CD33 ANTIBODIES AND IMMUNOCONJUGATES Genentech, Inc. (US) 2019-04-03 EP disclosed
US-10196454-B2 Anti-PMEL17 antibodies and immunoconjugates GENENTECH, INC. (US) 2019-02-05 US disclosed
EP-3080164-B1 ANTI-CD33 ANTIBODIES AND IMMUNOCONJUGATES GENENTECH INC (US) 2019-01-16 EP disclosed
EP-2869850-B1 IMMUNOCONJUGATES COMPRISING ANTI-CD79B ANTIBODIES GENENTECH INC (US) 2017-08-23 EP disclosed
EP-2852404-B1 ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE GENENTECH INC (US) 2017-07-26 EP disclosed
WO-2015143004-A9 TARGETED THERAPEUTICS SYNTA PHARMACEUTICALS CORP. (US) 2016-09-29 WO disclosed
WO-2015143004-A1 TARGETED THERAPEUTICS SYNTA PHARMACEUTICALS CORP. (US) 2015-09-24 WO disclosed
WO-2015134464-A2 TARGETED THERAPEUTICS SYNTA PHARMACEUTICALS CORP. (US) 2015-09-11 WO disclosed
WO-2013158644-A2 TARGETED THERAPEUTICS SYNTA PHARMACEUTICALS CORP. (US) 2013-10-24 WO disclosed
WO-2010009124-A2 ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS GENENTECH, INC. (US) 2010-01-21 WO disclosed
WO-2009099741-A1 NEMORUBICIN METABOLITE AND ANALOG REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS GENENTECH, INC. (US) 2009-08-13 WO disclosed
EP-0829104-A1 HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1998-03-18 EP disclosed
WO-1996035239-A1 HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1996-11-07 WO disclosed